Astria Therapeutics, Inc. (ATXS)

NASDAQ: ATXS · IEX Real-Time Price · USD
-0.12 (-2.55%)
Nov 28, 2023, 4:00 PM EST - Market closed

Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.

Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema.

The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.

Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Astria Therapeutics, Inc.
Astria Therapeutics logo
Country United States
Founded 2008
IPO Date Jun 25, 2015
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Ms. Jill C. Milne Ph.D.

Contact Details

75 State Street, Suite 1400
Boston, Massachusetts 02109
United States
Phone 617-349-1971

Stock Details

Ticker Symbol ATXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001454789
CUSIP Number 04635X102
ISIN Number US04635X1028
SIC Code 2834

Key Executives

Name Position
Jill C. Milne Ph.D. Co-Founder, Chief Executive Officer, President and Director
Noah Clauser CPA Chief Financial Officer
Dr. Andrew J. Nichols Ph.D. Chief Scientific Officer
Benjamin S. Harshbarger J.D. Chief Legal Officer
Keri McGrail Senior Vice President of Human Resources
Andrea L. Matthews Senior Vice President of Corporate Affairs
Andrew A. Komjathy Chief Commercial Officer
Dr. Anthony Christopher Stevens M.D. Interim Chief Medical Officer
Dr. Christopher J. Morabito M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 13, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report
Oct 18, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 12, 2023 8-K Current Report
Oct 12, 2023 424B5 Filing
Oct 12, 2023 8-K Current Report
Oct 12, 2023 FWP Free Writing Prospectus
Oct 11, 2023 8-K Current Report
Aug 7, 2023 S-8 Securities to be offered to employees in employee benefit plans
Aug 7, 2023 10-Q Quarterly Report